Scientists have found one of the most widely prescribed pain and anti-inflammation drugs has potential to slow the growth of cancer.
The study showed that the drug slows the growth rate of a specific kind of cancer in animal models and suggests the medication could have the same effect on other types of tumours.
The research focused on the drug which targeted an enzyme called "cyclooxygenase-2", which is linked to pain and inflammation.
The researchers conducted animal studies tracking the effects of celecoxib on the growth of cancer cells from a tumour type known as neurofibromatosis type II.
In humans, NF2 is a relatively rare inherited form of cancer caused by mutations in the anti-tumour gene NF2, which leads to benign tumours of the auditory nerve.
Animals received a daily dose of the drug, and tumour growth was followed by imaging.
Analysis of the results showed a significantly slower tumour growth rate in celecoxib-treated models than in controls.